An "artificially intelligent nanoarray" can offer a fast and inexpensive diagnosis of 17 diseases, by identifying their unique chemical signatures in your breath.
An international team of researchers led by Professor Hossam Haick of the Technion-Israel Institute of Technology has proven an ancient hypothesis that certain diseases can be detected through a patient's breath, which could lead to a future of quick and non-invasive tests for early detection of those diseases.
The team's research, which was published in the journal ACS Nano, used breath samples collected from 1404 subjects, each of which were previously diagnosed as having one of 17 different disease conditions, and used "an artificially intelligent nanoarray based on molecularly modified gold nanoparticles and a random network of single-walled carbon nanotubes" to detect and quantify chemical compounds in the samples.
"Each of these diseases is characterized by a unique fingerprint, meaning a different composition of these 13 chemical components. Just as each of us has a unique fingerprint that distinguishes us from others, each disease has a chemical signature that distinguishes it from other diseases and from a normal state of health. These odor signatures are what enables us to identify the diseases using the technology that we developed.” - Haick
Although the system isn't quite ready for use in diagnosis by the wider medical community, according to Technion, the team's work has been able to detect and classify various diseases "with an average accuracy of 86%."
"This is a new and promising direction for diagnosis and classification of diseases, which is characterized not only by considerable accuracy but also by low cost, low electricity consumption, miniaturization, comfort and the possibility of repeating the test easily.” - Haick
The study used breath samples from patients with lung cancer, colorectal cancer, head and neck cancer, ovarian cancer, bladder cancer, prostate cancer, kidney cancer, stomach cancer, Crohn’s disease, ulcerative colitis, irritable bowel syndrome, Parkinson’s disease (two types), multiple sclerosis, pulmonary hypertension, preeclampsia and chronic kidney disease. An analysis using the artificially intelligent nanoarray showed that "each disease has its own unique breathprint," and the presence of one disease "would not screen out others." According to the published findings, the team found that "13 exhaled chemical species, called volatile organic compounds, are associated with certain diseases, and the composition of this assembly of volatile organic compounds differs from one disease to another."
Perhaps one day soon, we'll all be able to include a quick 'breathalyzer' test at regular checkups to increase the chances of early detection of certain diseases, which will enable early treatment and potentially a more promising outcome.